参芪扶正注射液联合多西他赛治疗中晚期非小细胞肺癌

目的:运用参芪扶正注射液配合化疗,观察化疗患者骨髓抑制、消化道反应、KPS评分变化。方法:将符合纳入标准的肺癌化疗病人100例,应用信封法随机分组,实验组应用PD方案化疗,同时配合使用参芪扶正注射液;对照组单纯应用PD方案化疗。观察参芪扶正注射液对化疗所致的骨髓抑制、消化道反应、KPS体力状况评分的影响。结果:实验组WBC,NEU降低程度明显小于对照组(P<0.05);实验组恶心、腹泻症状明显轻于对照组(P<0.05);实验组KPS体力状况评分降低程度极明显小于对照组(P<0.01)。结论:参芪扶正注射液能减轻化疗后血WBC、NEU的下降程度,减轻化疗引起的恶心、腹泻症状,改善化疗后患者的KPS体力状况评分。     

当归补血汤相状态的研究

目的:研究当归补血汤提取液的相状态。方法:通过HPLC检测阿魏酸、HPLC-ELSD检测黄芪甲苷、紫外分光光度法检测总多糖、双缩脲法检测蛋白质,并以激光衍射法检测粒径和粒径分布,结合光学现象,描述当归补血汤的相状态。结果:可以测得当归补血汤中阿魏酸、黄芪甲苷、总多糖和蛋白质的含量,提取液中分散相质点的粒径主要分布于50～100 nm和1 000 nm以上,并可以观察到明显的丁达尔现象。结论:当归补血汤含有以均相状态存在的真溶液和非均相状态存在的胶体溶液、混悬液或乳浊液,为混合分散体系。     

扶正固本Ⅰ号方结合化疗治疗晚期非小细胞肺癌疗效观察

目的观察扶正固本Ⅰ号方结合化疗治疗非小细胞肺癌（NSCLC）的临床疗效。方法将107例NSCLC患者随机分为对照组（53例,单纯化疗治疗）和治疗组（54例,化疗结合扶正固本Ⅰ号方治疗）。4个周期后,观察两组临床疗效、血液学毒性反应发生情况和远期疗效。结果治疗组的近期有效率为16.7%、稳定率为88.9%,均高于对照组的7.5%和54.7%（P〈0.05）;治疗组的血液学毒性发生率为63.0%,对照组为81.1%（P〈0.05）;治疗组的无进展时间和中位生存期均长于对照组（P〈0.05）。结论扶正固本Ⅰ号方治疗NSCLC疗效确切,能明显减轻毒副反应,延长生存期。     

参芪扶正注射液联合FOLFOX4方案化疗治疗晚期胃癌疗效观察

目的 评价参芪扶正注射液联合FOLFOX4方案(奥沙利铂加亚叶酸钙和5-氟尿嘧啶)治疗晚期胃癌的综合疗效和不良反应.方法 将70例晚期胃癌患者随机分两组,对照组34例,单用FOLFOX4方案化疗.治疗组36例,在对照组治疗的基础上加用参芪扶正注射液250 ml静脉滴注,1次/d,连用10 d.结果 两组疗效比较差异无统计学意义(P>0.05);治疗组血液不良反应和消化道不良反应发生率明显低于对照组,差异有统计学意义(P<0.05).结论 参芪扶正注射液联合FOLFOX4方案治疗晚期胃癌可降低化疗引起的不良反应,改善患者的生活质量. Abstract： Objective To observe the efficacy and toxicity of Shenqi Fuzheng injection combined with FOLFOX4 chemo-therapy to treat patients with advanced Gastric cancer.Methods Seventy patients were randomly divided into two groups by random assignment,control group(34 patients were treated by FOLFOX4 only) and treatment group(36 patients were treated by combining Shenqi Fuzheng injection and FOLFOX4).Shenqi Fuzheng injection 250 ml Qd for 10 days in the treated group. Results Difference between the two groups on therapeutic effect showed no significance(P>0.05). The hematological toxicity and gastrointestinal reactions in the treated group were lower than those in the control group with significant difference(P<0.05).Conclusions When used to treat patients with advanced Gastric cancer Shenqi Fuzheng injection combined with FOLFOX4 regimen were more effective and with lower toxicities.     

基于有效组分检测与理化表征相结合的当归补血汤制备工艺与质量控制研究

目的 优选当归补血汤的制备工艺,探索以理化表征参数作为汤剂制备工艺评价与质量控制手段的可行性。方法 采用正交试验设计,主要以有效组分阿魏酸、黄芪甲苷、黄芪皂苷、多糖的量为指标,全面考察当归补血汤的制备工艺,并对所得提取液进行流变学、表面化学、电化学等方面的表征,将表征参数与组分的量进行多项式回归分析。结果 优选的当归补血汤制备工艺条件为取处方药材加12倍量水,提取3次,每次1.0 h;理化表征显示,不同制备工艺条件所得汤剂理化参数差别较大,且渗透压与体系组分的量关系最为密切,表面张力、电导率次之,而pH值、黏度与体系组分的量关系不密切。结论 初步表明,表面张力、电导率和渗透压可作为当归补血汤制备工艺与质量控制的评价指标,通过提取液的理化表征来进行质量控制具有一定的可行性。     

Fuzheng Huayu Capsule (扶正化瘀胶囊) in the treatment of liver fibrosis: Clinical evidence and mechanism of action

Liver fibrosis represents the wound healing response to liver injury from a wide variety of etiologies.Remarkable progresses have been shown in the field of liver fibrosis in a range of areas in the past years.In particular,the reversibility of liver fibrosis has been well documented in both patients and animal models.Great progresses have been made in the treatment of liver fibrosis with Chinese medicine.This review summarizes the effects of Fuzheng Huayu Capsule(扶正化瘀胶囊,FZHYC) in treating liver fibrosis and inflammation induced by chronic hepatitis B in clinical trials and the mechanism of action of FZHYC in reversing liver fibrosis in vivo and in vitro experiments.     

傅青主“加减当归补血汤”治疗更年期崩漏30例

目的观察傅青主"加减当归补血汤"治疗更年期崩漏的疗效。方法选取更年期崩漏确诊病例30例,以傅青主"加减当归补血汤"为主方,每日1剂,分早晚两次温服,3剂为1个疗程。结果 30例中有效26例,无效4例,总有效率86.67%。结论傅青主"加减当归补血汤"治疗更年期崩漏有较好疗效,且无明显不良反应,值得临床推广,但仍需作进一步研究。     

参芪扶正注射液延缓慢性肾衰竭临床与实验研究

目的：客观评价参芪扶正注射液治疗慢性肾功能衰竭（CRY）的疗效及安全性。方法：临床观察随机分组,治疗组（120例）给予参芪扶正注射液,对照组（60例）给予尿毒清;实验研究选取雌、雄性小鼠,随机分为正常对照组,模型组和参芪扶正注射液药物大、小剂量组,分别做负重游泳、灌胃急毒、动物模型治疗。结果：临床疗效治疗组明显优于对照组;实验动物无急性毒性反应,大剂量能显著提高小鼠抗疲劳能力及免疫功能,能较好地改善肾功能。结论：参芪扶正注射液无毒副作用,能维护和改善肾功能,从而延缓慢性肾功能衰竭的进程和延长病人的寿命。     

Effects of a Shuangling Fuzheng anticancer preparation on the proliferation of SGC-7901 cells and immune function in a cyclophosphamide-treated murine model

AIM: To study the inhibitory effects of a Shuangling Fuzheng anticancer preparation (SFAP) on the human gastric cancer cell line SGC-7901 in vitro as well as its immune-modulated effects in a cyclophosphamide-treated murine model. METHODS: MTT experiments and immunocytochemistry ABC experiments were performed for detecting the proliferation of SGC-7901 cells in vitro and protein expression of c-myc. The staphylococcal protein A (SPA) rosette test was utilized for measuring the ratio of T-lymphocyte subsets from peripheral blood in a cyclophosphamide-treated murine model. Enzyme- linked immunosorbant assay (ELISA) was performed for measuring the levels of serum sIL-2R in treated mice, while immunoturbidimetry was used for measuring the levels of immunoglobulins (Ig). RESULTS: SFAP (40-640 mg/L, 48 h) inhibited the proliferation of SGC-7901 cells, and a positive correlation was noted between inhibitory effects and dosage. At a dosage of 160-320 mg/L in cultured cells, the expression of c-myc was decreased. SFAP (50-200 mg/kg) increased the percentage of CD3 and CD4 T-lymphocytes, the ratio of CD4/CD8, and the contents of Ig such as IgM, IgG or IgA, but decreased the levels of serum sIL-2R in peripheral blood from cyclophosphamide-treated mice. CONCLUSION: SFAP can inhibit the proliferation of SGC-7901 cells via the c-myc gene. In addition, SFAP can modulat the cellular and humoral immunity in cyclophosphamide-induced immunosuppressed mice.     

阿胶补血口服液中黄芪甲苷含量的测定

目的：建立测定中成药阿胶补血口服液中黄芪甲苷的含量。方法：采HPLC—ELSD色谱法,色谱柱：HypereloneBDS柱（150×4．6mm,5μm）;检测波长：286nm;流动相：乙腈-水（32：68）;流速：1．0ml／min。结果：黄芪甲苷在0．525-5．25μg范围内具有良好的线性关系,r=0．9997;平均回收率为99．04％,RSD=1．79％。结论：该法灵敏度高、专属性强、重现性好,并通过对数批样品含量进行考察．町作为制剂质量控制指标之一。